Stats by Source
Total, split by cell line (COSMIC CL / DepMap / PubMed) vs tissue (COSMIC primary tissue)
Total = all mutations for this gene across every source.
Cell line = COSMIC Cell Lines Project + DepMap + PubMed.
Tissue = COSMIC primary-tissue (patient tumour) samples.
Total can exceed cell line + tissue: COSMIC tissue-derived models sit only in global, and a peptide can be shared across both.
| Total | Cell line | Tissue | |
|---|---|---|---|
| Mutations | 2,150 | 290 | 1,853 |
| Samples | 461 | 87 | 372 |
| Peptides | 408 | 73 | 351 |
Function
CDH16 · Cadherin 16
This gene is a member of the cadherin superfamily, genes encoding calcium-dependent, membrane-associated glycoproteins. Mapped to a previously identified cluster of cadherin genes on chromosome 16q22.1, the gene localizes with superfamily members CDH1, CDH3, CDH5, CDH8 and CDH11. The protein consists of an extracellular domain containing 6 cadherin domains, a transmembrane region and a truncated cytoplasmic domain but lacks the prosequence and tripeptide HAV adhesion recognition sequence typical of most classical cadherins. Expression is exclusively in kidney, where the protein functions as the principal mediator of homotypic cellular recognition, playing a role in the morphogenic direction of tissue development. Alternatively spliced transcript variants encoding distinct isoforms have been identified. [provided by RefSeq, Mar 2011].
Isoforms & Proteins
5 transcripts · UniProt mapping is sequence-verified (AA-safe)
Each Ensembl transcript (ENST) this gene is mutated on, with its matched UniProt accession.
The mapping is sequence-verified: the UniProt sequence is identical to the transcript translation, so amino-acid positions line up exactly. A * marks an unreviewed (TrEMBL) entry.
Counts are mutations and unique mutant peptides on each transcript.
Gene Properties
Recurrent Mutations
All 366 amino-acid changes on canonical ENST00000299752 · needle height = samples · drag the mini-map to zoom
A lollipop / needle plot – the standard way to show recurrent mutations along a protein (as used by cBioPortal and MutationMapper).
X-axis = amino-acid position in the protein.
Needle height & head size = how often that exact amino-acid change was observed (its recurrence). Tall/large heads are mutational hotspots.
The most recurrent changes are labelled; hover any needle for the change, position and counts.
Mutation frequency across cancer types
% of samples with a missense/complex mutation in CDH16 · cell line vs tissue
For each cancer type, the fraction of samples that carry at least one missense/complex mutation anywhere in CDH16 – counted as distinct samples (a sample counts once no matter how many mutations it has).
Split into cell line and tissue; each cell shows mutated / total and the percentage. Cohorts with <20 samples are omitted. Ordered by combined frequency.
| Cancer type | Cell lines | Tissue samples |
|---|---|---|
| Oral Cavity Carcinoma | 3/54 6% | 0/0 0% |
| T-Lymphoblastic Leukemia | 2/40 5% | 0/0 0% |
| Melanoma | 7/210 3% | 74/1899 4% |
| Hodgkins Lymphoma | 4/16 25% | 1/122 1% |
| Endometrial Carcinoma | 4/42 10% | 19/612 3% |
| Acute Myeloid Leukemia | 2/90 2% | 0/0 0% |
| Other Solid Cancers | 2/94 2% | 32/1515 2% |
| Non-Small Cell Lung Carcinoma | 12/304 4% | 18/1390 1% |
| Squamous Cell Lung Carcinoma | 3/57 5% | 12/810 1% |
| Colorectal Carcinoma | 9/143 6% | 48/3239 1% |
| Gastric Carcinoma | 2/74 3% | 25/1809 1% |
| Bladder Carcinoma | 1/58 2% | 12/956 1% |
| Cervical Carcinoma | 0/35 0% | 5/422 1% |
| Small Cell Lung Carcinoma | 0/9 0% | 8/752 1% |
| Head and Neck Carcinoma | 3/85 4% | 14/1574 1% |
| Ovarian Carcinoma | 6/109 6% | 5/998 0% |
| Neuroendocrine Tumour | 5/154 3% | 1/577 0% |
| Biliary Tract Carcinoma | 1/54 2% | 7/950 1% |
| Gastrointestinal Stromal Tumour | 0/0 0% | 1/133 1% |
| Glioma | 3/52 6% | 13/2127 1% |
| Other Sarcomas | 2/69 3% | 3/699 0% |
| Non-Cancerous | 1/104 1% | 5/830 1% |
| Plasma Cell Myeloma | 2/44 5% | 0/305 0% |
| Germ Cell Tumour | 1/25 4% | 0/169 0% |
| Hepatocellular Carcinoma | 0/46 0% | 11/2210 0% |
| Prostate Carcinoma | 2/13 15% | 7/2105 0% |
| Esophageal Squamous Cell Carcinoma | 2/51 4% | 8/2550 0% |
| Thyroid Gland Carcinoma | 0/45 0% | 6/1592 0% |
| Kidney Carcinoma | 1/85 1% | 6/1862 0% |
| Neuroblastoma | 3/87 3% | 2/1331 0% |
Mutation Distribution
Where CDH16 is mutated · all tissues, split by cell line vs tissue
How many mutations in CDH16 were found in each tissue, across the whole database.
Each bar is a tissue (cell-line and tissue names are merged to the standard tissue), split into cell line and tissue (patient tumour) contributions.
This shows the cancer-context where this gene is recurrently altered.
GTEx Expression
Median TPM across 52 healthy tissues
Median gene expression (TPM) in normal, non-cancer human tissues from the GTEx project.
Useful for judging tumour specificity – a strong neoantigen target ideally comes from a gene with low expression in healthy tissues.
Scroll or drag the mini-axis below the chart to browse all tissues.
Mutations
All 2,150 mutations in CDH16
Every mutation record for this gene, across all samples and sources.
The Sample column links to the cell line (cell-line samples) or the tissue type (tissue samples).
Use the Type / Source filters, the search box, and column sorting to explore; each CAN-IMMUNE ID opens the full mutation & peptide view.
| ID | Sample | Transcript | AA Change | CDS | Type | Source | Mutant Peptide | Wild-type Peptide |
|---|